Serina Therapeutics Management
Management criteria checks 0/4
Serina Therapeutics' CEO is Steve Ledger, appointed in Mar 2024, has a tenure of 1.17 years. total yearly compensation is $3.70M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 0.96% of the company’s shares, worth $544.71K. The average tenure of the management team and the board of directors is 1 years and 1.1 years respectively.
Key information
Steve Ledger
Chief executive officer
US$3.7m
Total compensation
| CEO salary percentage | 8.81% |
| CEO tenure | 1.2yrs |
| CEO ownership | 1.0% |
| Management average tenure | less than a year |
| Board average tenure | 1.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$939k |
| Dec 31 2024 | US$4m | US$326k | -US$11m |
| Sep 30 2024 | n/a | n/a | -US$7m |
| Jun 30 2024 | n/a | n/a | -US$7m |
| Mar 31 2024 | n/a | n/a | -US$11m |
| Dec 31 2023 | US$238k | US$170k | US$5m |
Compensation vs Market: Steve's total compensation ($USD3.70M) is above average for companies of similar size in the US market ($USD650.80K).
Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.
CEO
Steve Ledger (65 yo)
1.2yrs
Tenure
US$3,703,621
Compensation
Mr. Steven A. Ledger, also known as Steve, was the Founder of Tamalpais Partners LLC and served as its Managing Partner since January 2009 until 2012. Mr. Ledger has experience as an investor in emerging t...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.1yrs | US$3.04m | 0% $ 0 | |
| CEO & Director | 1.2yrs | US$3.70m | 0.96% $ 544.7k | |
| Co-Founder | no data | US$438.37k | 0% $ 0 | |
| Chief Financial Officer | less than a year | US$1.70m | 0% $ 0 | |
| Senior Vice President of Chemistry | less than a year | US$1.78m | no data | |
| Chief Development Officer | no data | US$433.88k | 0% $ 0 |
1.0yrs
Average Tenure
63.5yo
Average Age
Experienced Management: SER's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.1yrs | US$3.04m | 0% $ 0 | |
| CEO & Director | 1.2yrs | US$3.70m | 0.96% $ 544.7k | |
| Co-Founder | less than a year | US$438.37k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 1.2yrs | US$433.11k | 0.68% $ 382.6k | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 1.2yrs | US$433.11k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$436.12k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
1.1yrs
Average Tenure
61yo
Average Age
Experienced Board: SER's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 06:14 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Serina Therapeutics, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Walsh | JonesTrading Institutional Services, LLC |